NEWS & EVENTS
Company News
Press Release
For Immediate Release
May 11, 2009
Contact: Gregg DiPietro
Leerink Swann
(617) 918-4601
Gregg.DiPietro@leerink.com
Contacts: Risa Goldman Burgess or Justin Drake
Schwartz Communications
(781) 684-0770
leerink@schwartz-pr.com
Leerink Swann to Host Novel Cancer Therapeutics Conference
Roundtable Sessions to Feature Healthcare Industry Leaders Discussing Emerging Oncology Trends and Challenges
Boston, MA—May 11, 2009—Leerink Swann, the leading healthcare investment banking firm, today announced it will host a one day conference on novel cancer therapeutics at the Roosevelt Hotel in New York City on Wednesday, May 20 from 7:30 a.m. to 4:30 p.m.
The conference, chaired by Leerink Swann Biotechnology Analyst Howard Liang, Ph.D., will feature senior management from companies that are developing novel therapeutics for cancer, who will discuss the latest advances and challenges facing the industry. Leading institutional investors, hedge funds and venture capital firms in healthcare will participate.
Panels will also include key opinion leaders from MEDACorp, Leerink Swann’s proprietary network of almost 30,000 healthcare experts.
"With Leerink Swann’s highly specialized and differentiated focus on the healthcare sector, we view cancer diagnostics and therapeutics as a critically important subject for dialogue with key opinion leaders,” said John Sullivan, Director of Research and Healthcare Strategist at Leerink Swann. “Leerink Swann’s roundtable series has evolved into an essential event for institutional investors, venture capitalists, hedge funds, banks and company executives to glean perspective and insights in an unrivaled format. We look forward to a very productive conference and many lively discussions among our esteemed participants.”
The roundtable conference on novel cancer developments is the latest in a series of roundtables hosted by Leerink Swann on a range of healthcare topics. For a list of past Leerink Swann events, please visit http://www.leerink.com/news--events/past-conferences.aspx.
Accredited media interested in attending the open sessions at the conference should contact Risa Goldman Burgess or Justin Drake of Schwartz Communications at 781-684-0770 or by email at leerink@schwartz-pr.com to register for the event.
About Leerink Swann
Leerink Swann is a healthcare-focused investment banking firm that provides equity research, corporate finance, strategic advisory, and asset management services for institutional, life sciences, and high-net-worth clients. Every year since 2001, Institutional Investor has named Leerink Swann “Best of the Boutiques” in several healthcare categories. Through its MEDACorp division, Leerink Swann provides biomedical-consulting services to the institutional investment community. With an internal team of experts and a dedicated external network of academic and community healthcare professionals, MEDACorp assesses the viability of cutting-edge medical technologies, thus giving decision makers the information they need to perform. Leerink Swann is a member of FINRA/SIPC. For more information, visit www.leerink.com.